UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000051091
Receipt number R000058265
Scientific Title Validation study of an evaluation method for non-invasive measurement of blood hemoglobin concentration
Date of disclosure of the study information 2023/05/20
Last modified on 2023/05/17 22:44:04

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Test of an evaluation method to measure blood hemoglobin concentration without harming the body

Acronym

Test of an evaluation method for intact measurement of blood hemoglobin concentration

Scientific Title

Validation study of an evaluation method for non-invasive measurement of blood hemoglobin concentration

Scientific Title:Acronym

Validation study of an evaluation method for non-invasive measurement of blood Hb concentration

Region

Japan


Condition

Condition

Not applicable

Classification by specialty

Laboratory medicine Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Validate a non-invasive method of measuring blood hemoglobin concentration.

Basic objectives2

Bio-equivalence

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

-Blood hemoglobin concentration calculated by this measurement method
-Blood hemoglobin concentration by colorimetric method

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

25 years-old <=

Age-upper limit

35 years-old >=

Gender

Male and Female

Key inclusion criteria

Healthy male and female the ages of 25 and 35

Key exclusion criteria

1. Person who has a disease currently treatment.
2. Person who takes medications (antihypertensive, sleeping pills, antiallergic, sedatives, hormones, and other medications for illnesses).
3. Person who has thin (BMI < 18.5) or overweight (BMI > 30.0).
4. Person who has pregnant or possibly pregnant.
5. Person who currently has fever symptoms, rhinitis symptoms, or atopic symptoms.
6. Person who has ever smoked.
7. Person who has external injury to the measurement site (the ring finger of the non-dominant arm).
8. Person who deemed inappropriate by the investigator and study personnel.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Kiyoshi
Middle name
Last name Kataoka

Organization

Kao Corporation

Division name

Personal Health Care Products Research Lab.

Zip code

131-8501

Address

2-1-3, Bunka, Sumida-ku, Tokyo, 131-8501, JAPAN

TEL

+81-3-5630-7486

Email

kataoka.kiyoshi@kao.com


Public contact

Name of contact person

1st name Yoshinao
Middle name
Last name Nagashima

Organization

Kao Corporation

Division name

Personal Health Care Products Research Lab.

Zip code

131-8501

Address

2-1-3, Bunka, Sumida-ku, Tokyo, 131-8501, JAPAN

TEL

+81-3-5630-7486

Homepage URL


Email

nagashima.yoshinao@kao.com


Sponsor or person

Institute

Kao Corporation

Institute

Department

Personal name



Funding Source

Organization

Kao Corporation

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

CPCC Company Limited

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Human Research Ethics Committee, Kao Corporation

Address

2-1-3 Bunka, Sumida-ku, Tokyo 131-8501, JAPAN

Tel

+81-3-5630-9064

Email

morisaki.naoko@kao.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

チヨダパラメディカルケアクリニック(東京都)


Other administrative information

Date of disclosure of the study information

2023 Year 05 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2023 Year 01 Month 27 Day

Date of IRB

2023 Year 01 Month 27 Day

Anticipated trial start date

2023 Year 05 Month 20 Day

Last follow-up date

2023 Year 10 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Association analysis between this measurement method and the colorimetric method in blood hemoglobin concentration.


Management information

Registered date

2023 Year 05 Month 17 Day

Last modified on

2023 Year 05 Month 17 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000058265


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name